Department of Urology, Clinica Las Condes; Department of Urology, Hospital Militar, Santiago, Chile.
Department of Urology, Hospital Militar, Santiago, Chile.
Int Braz J Urol. 2014 Mar-Apr;40(2):154-9. doi: 10.1590/S1677-5538.IBJU.2014.02.04.
Active surveillance (AS) has become an accepted alternative for patients with low risk prostate cancer. The purpose of AS is to defer definitive therapy in these patients to avoid treatment-related complications. Our aim was to determine the pathological features of the surgical specimen from potential AS candidates that underwent radical prostatectomy (RP).
We retrospectively reviewed a group of patients submitted to RP who met criteria for AS: Gleason score (GS) ≤ 3+3 = 6, PSA ≤ 10ng/mL, T1c - T2a,< 1/3 of positive cores, < 50% of involvement in any core and PSA density < 0.15. We determined the concordance between GS in biopsy and RP specimen (RPS). Other pathological features of the RPS were also analyzed, including surgical margins, extracapsular extension, seminal vesicles and lymph node involvement.
We identified 167 patients subjected to RP that met the criteria for AS. Fifty two patients (31.1%) had a GS > 6 in the RPS (GS 7 n = 49; GS 8 n = 3). Extracapsular extension, seminal vesicle and lymph node involvement was found in 6.1%, 3.1% and 1.2% of the specimens, respectively.
In this study a significant proportion of potential candidates for AS showed features of aggressive and/or high-risk tumors in the RPS. Therefore, before considering a patient for an AS protocol, a proper and strict selection must be performed, and informed consent is crucial for these patients.
主动监测(AS)已成为低危前列腺癌患者的一种可接受的替代治疗方法。AS 的目的是延迟这些患者的确定性治疗,以避免与治疗相关的并发症。我们的目的是确定接受根治性前列腺切除术(RP)的潜在 AS 候选者的手术标本的病理特征。
我们回顾性分析了一组符合 AS 标准的接受 RP 的患者:Gleason 评分(GS)≤3+3=6,PSA≤10ng/mL,T1c-T2a,阳性核心<1/3,任何核心的受累程度<50%,PSA 密度<0.15。我们确定了活检和 RP 标本(RPS)中 GS 的一致性。还分析了 RPS 的其他病理特征,包括手术切缘、包膜外延伸、精囊和淋巴结受累。
我们确定了 167 名符合 AS 标准的接受 RP 的患者。52 名患者(31.1%)在 RPS 中 GS>6(GS7n=49;GS8n=3)。包膜外延伸、精囊和淋巴结受累分别在 6.1%、3.1%和 1.2%的标本中发现。
在这项研究中,相当一部分潜在的 AS 候选者在 RPS 中显示出侵袭性和/或高危肿瘤的特征。因此,在考虑患者是否进行 AS 方案之前,必须进行适当和严格的选择,并且这些患者的知情同意至关重要。